A5053416723- Salivary Gland Tumors Diagnosis and Treatment
- Ear and Head Tumors
- Head and Neck Cancer Studies
- Sarcoma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Airway Management and Intubation Techniques
- Lung Cancer Treatments and Mutations
- Peptidase Inhibition and Analysis
- Thyroid and Parathyroid Surgery
- Neuroblastoma Research and Treatments
- CAR-T cell therapy research
- Inflammatory mediators and NSAID effects
- Oral and Maxillofacial Pathology
- Immune Cell Function and Interaction
- Tracheal and airway disorders
Niigata Cancer Center Hospital
2024-2025
Niigata University Medical and Dental Hospital
2024
Hokkaido University
2024
Niigata University
2023-2024
To assess the efficacy and safety of apalutamide plus goserelin for androgen receptor (AR)-positive unresectable or recurrent/metastatic salivary gland carcinoma.
Abstract Introduction Immune‐related adverse events (irAEs) are prognostic factors for patients on nivolumab. However, predictors of irAEs have not yet been identified. We aimed to investigate the occurrence and nivolumab discontinuation due irAEs. Methods Sixty‐two with recurrent/metastatic head neck squamous cell carcinoma received therapy between June 2017 December 2020. Treatment outcome was compared groups or without The irAE (+) group further divided by discontinuation....
<p>Supplementary Materials for Apalutamide and Goserelin Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase 2 Nonrandomized Clinical Trial, YATAGARASU</p>
<div>AbstractPurpose:<p>To assess the efficacy and safety of apalutamide plus goserelin for androgen receptor (AR)–positive unresectable or recurrent/metastatic salivary gland carcinoma.</p>Patients Methods:<p>This trial was an open-label, single-arm, multicenter phase II study. Patients with histologically confirmed carcinoma AR expression were included. The primary endpoint overall response rate (ORR) according to RECIST v1.1 by independent central radiology review...
<p>Supplementary Materials for Apalutamide and Goserelin Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase 2 Nonrandomized Clinical Trial, YATAGARASU</p>
<div>AbstractPurpose:<p>To assess the efficacy and safety of apalutamide plus goserelin for androgen receptor (AR)–positive unresectable or recurrent/metastatic salivary gland carcinoma.</p>Patients Methods:<p>This trial was an open-label, single-arm, multicenter phase II study. Patients with histologically confirmed carcinoma AR expression were included. The primary endpoint overall response rate (ORR) according to RECIST v1.1 by independent central radiology review...
<p>Supplementary Materials for Apalutamide and Goserelin Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase 2 Nonrandomized Clinical Trial, YATAGARASU</p>
<p>Supplementary Materials for Apalutamide and Goserelin Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase 2 Nonrandomized Clinical Trial, YATAGARASU</p>
Radiation-induced osteosarcoma (RIOS) is a rare and refractory late-stage complication of radiotherapy for head neck cancer. Unlike de novo osteosarcoma, there are only few treatment options RIOS owing to its rapid progression, particularly in elderly who have received multimodal treatments including full-dose radiation chemotherapies. Recently, genomic analysis has emerged as potential approach identify specific therapeutic targets cancers such RIOS. A 61-year-old male developed the maxilla...